5th Nordic Pathology Meeting on Pathology & Biomarkers in thoracic malignancies, primarily NSCLC

2000 kr

Artikelnr: 2143 Kategorier: ,



Danish Lung Pathologists Group, Danish Oncology Lung Cancer Group, Finnish Lung Cancer Group, Swedish Molecular Pathology Group, Swedish Society of Pathology, Swedish Lung Cancer Study Group and a Nordic Pathology Network steering committee. Cancer Academy North


Invites you to:

5th Nordic Pathology Meeting on Pathology & Biomarkers in thoracic malignancies, primarily NSCLC

Clarion Hotel Arlanda, Sweden – 31 January – 1 February 2019

Steering committee:

Birgit Guldhammer Skov (DK), Elisa Lappi-Blanco (FIN), Fredrik Enlund (S),
Lars Helgeland (NO), Jens Benn Sørensen (DK), Simon Ekman (S)


The objectives of the meeting are to highlight the latest developments – Pathology, Oncology and Technology. How can we use improved technology to advice on optimal treatments in lung cancer in a constantly changing environment? Please see preliminary program for the meeting.

Who should attend the meeting? Pathologists, Molecular biologists, Lung oncologists, Pulmonologists, and other interested in the field of Lung Cancer. Residents as well as consulting doctors should attend the meeting.

Language: English

Number of Participants: 150

Form of Symposium: Lectures and discussion

Registration Fee: 2000 SKR

Application deadline: January 15, 2019

What is included in the registration fee?
Admission to all scientific sessions
Admission to exhibition
Final Program
Coffee/tea during breaks
Dinner January 31th

Hotel rooms during the meeting
Hotel rooms are pre-booked with discounted rate at Clarion Hotel Arlanda, (arrival January 31th for one night). Rooms and reduced price is guaranteed until November 30. After that date we can’t guarantee room or price.

For hotel booking – click here

NOTE! Hotel rooms are not included in the congress fee.  The hotel rooms have to be booked and paid by each participant.

We hope that this will be an interesting and productive meeting and look forward to see you at Clarion Hotel Arlanda – Stockholm in January 2019.



A Warme Welcome

Steering committee

Birgit Guldhammer Skov (DK)

Elisa Lappi-Blanco (FIN)

 Fredrik Enlund (S)

Lars Helgeland (NO)

Jens Benn Sørensen (DK) 

Simon Ekman (S)


If you have any questions – please contact Monica Sandström, tel: +46 90 – 785 28 55, e-mail: monica.sandstrom@umu.se


Skriv ut


January 31



IO and biomarkers - Birgit Guldhammer Skov, Denmark

10.00 - 10.10

Welcome to the meeting


10.10 - 10.40

PD-L1 as a biomarker for IO in NSCLC            

Keith Kerr, UK                    

10.45 - 11.15

PD-L1 on cytology

Birgit Guldhammer Skov, DK

11.15 – 11.45

Coffee break/exhibition


11.45 – 12.15

PD-L1 - NordiQC experiences

Mogens Vyberg, DK            

12.15 - 12.30

Discussions of the morning sessions

Birgit Guldhammer Skov, DK

12.30 – 13.30



13.30 – 14.00

Other biomarker for IO, including TMB

Keith Kerr, UK                 

14.05 – 14.35

PD-L1 prevalence in an unselected (Danish) population

Birgit Guldhammer Skov, DK

14.35 – 15.00

Coffee break/Exhibition





Oncogenic drivers and technologies - Simon Ekman, Fredrik Enlund, Sweden

15.00 – 15.30

Clinical aspects of fusion genes in NSCLC

Jussi Koivunen, FI

15.35 – 16.05

Molecular analyses of fusion genes

Fredrik Enlund, SE

16.05 – 16.15

Questions and answers


16.15 – 16.35

Short break


16.35 – 17.00

Targets beyond EGFR and ALK in NSCLC

Simon Ekman, SE

17.00 – 17.30

What to report and not to report in the molecular pathology report

Johan Botling, SE

17.30 – 17.40


Simon Ekman SE, Fredrik Enlund, SE

19.00 -




February 1



Oncogenic drivers and technologies - Simon Ekman, Fredrik Enlund, Sweden

08.00 – 08.25

An update on the use of EGFR TKIs in NSCLC

Odd Terje Brustugun, NO

08.30 – 08:50

Liquid biopsies in EGFR-mutation positive patients – when to use it and which methods

Juha Kononen, FI

08.50 – 09.05

Rebiopsy in EGFR TKI treated patients – when and how?

Juha Kononen, FI

09.05 – 09.20

Coffee break/Exhibition


09.20 – 10.00

Breakout sessions countrywise


10.00 – 10.20

Coffee break/Exhibition





MPM and SCLC – Jens Benn Sørensen, Denmark

10.20 – 10.50

Status on IO in MPM and SCLC (Clinical)

Jens Benn Sørensen, DK

10.50 – 11.20

Delta-like protein 3 (DLL3) ADC in SCLC - (Rova-T)

Seppo Langer, DK

11.20 – 11.50

MPM prognostic markers and potential therapeutic targets

Oluf Dimitri Røe, NO

11.50 – 12.25

Subtyping of Malignant Mesothelioma including reproducibility of biphasic mesothelioma: Data from the MESOPATH reference center

Francoise Galateau-Sallé, F

12.25 – 12.55

Genomic Medicin Sweden (GMS) and its implication on biomarker analysis in lung cancer

Richard Rosenquist Brandell

12.55 – 13.10

Discussion and Close up!

Organizing Committee

13.10 – 14.10





The meeting is sponsored by:


Skriv ut